Background Epidermal growth factor receptor (EGFR) inhibitors have shown only modest clinical activity when used as single agents to treat cancers. They decrease tumor cell expression of hypoxia-inducible factor 1-α (HIF-1α) and vascular endothelial growth factor (VEGF). Hypothesizing that this might normalize tumor vasculature, we examined the effects of the EGFR inhibitor erlotinib on tumor vascular function, tumor microenvironment (TME) and chemotherapy and radiotherapy sensitivity. Methodology/Principal Findings Erlotinib treatment of human tumor cells in vitro and mice bearing xenografts in vivo led to decreased HIF-1α and VEGF expression. Treatment altered xenograft vessel morphology assessed by confocal microscopy (following tomato lectin injection) and decreased vessel permeability (measured by Evan's blue extravasation), suggesting vascular normalization. Erlotinib increased tumor blood flow measured by Power Doppler ultrasound and decreased hypoxia measured by EF5 immunohistochemistry and tumor O2 saturation measured by optical spectroscopy. Predicting that these changes would improve drug delivery and increase response to chemotherapy and radiation, we performed tumor regrowth studies in nude mice with xenografts treated with erlotinib and either radiotherapy or the chemotherapeutic agent cisplatin. Erlotinib therapy followed by cisplatin led to synergistic inhibition of tumor growth compared with either treatment by itself (p<0.001). Treatment with erlotinib before cisplatin led to greater tumor growth inhibition than did treatment with cisplatin before erlotinib (p = 0.006). Erlotinib followed by radiation inhibited tumor regrowth to a greater degree than did radiation alone, although the interaction between erlotinib and radiation was not synergistic. Conclusions/Significance EGFR inhibitors have shown clinical benefit when used in combination with conventional cytotoxic therapy. Our studies show that targeting tumor cells with EGFR inhibitors may modulate the TME via vascular normalization to increase response to chemotherapy and radiotherapy. These studies suggest ways to assess the response of tumors to EGFR inhibition using non-invasive imaging of the TME.
References
[1]
Barcellos-Hoff MH, Cordes N (2007) Radiation therapy and the microenvironment. Int J Radiat Biol 83: 723–725.
[2]
Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1: 453–458.
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.
[5]
Quesada AR, Munoz-Chapuli R, Medina MA (2006) Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26: 483–530.
[6]
Zakarija A, Soff G (2005) Update on angiogenesis inhibitors. Curr Opin Oncol 17: 578–583.
[7]
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62.
[8]
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553–563.
[9]
Dutta PR, Maity A (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165–177.
[10]
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, et al. (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007.
[11]
Goldman CK, Kim J, Wong WL, King V, Brock T, et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121–133.
[12]
Maity A, Pore N, Lee J, Solomon D, O'Rourke DM (2000) Epidermal growth factor receptor (EGFR) transcriptionally upregulates VEGF expression in human glioblastoma cells via a pathway involving PI(3) kinase and distinct from that induced by hypoxia. Cancer Res 60: 5879–5886.
[13]
Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A (2003) PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63: 236–241.
[14]
Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541–1545.
[15]
Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391–396.
[16]
Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, et al. (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research 7: 1459–1465.
[17]
Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300–4306.
[18]
Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research 5: 257–265.
[19]
Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, et al. (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology 151: 1523–1530.
[20]
Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197–3204.
[21]
Wood AK, Bunte RM, Cohen JD, Tsai JH, Lee WM, et al. (2007) The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. Ultrasound Med Biol 33: 1901–1910.
[22]
Sehgal CM, Arger PH, Silver AC, Patton JA, Saunders HM, et al. (2001) Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. Radiology 219: 419–426.
[23]
Sehgal CM, Arger PH, Rowling SE, Conant EF, Reynolds C, et al. (2000) Quantitative vascularity of breast masses by Doppler imaging: regional variations and diagnostic implications. J Ultrasound Med 19: 427–440; quiz 441–422.
[24]
Solonenko M, Cheung R, Busch TM, Kachur A, Griffin GM, et al. (2002) In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. Phys Med Biol 47: 857–873.
[25]
Wang HW, Putt ME, Emanuele MJ, Shin DB, Glatstein E, et al. (2004) Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res 64: 7553–7561.
[26]
Koch CJ, Evans SM, Lord EM (1995) Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3？,3-pentafluoropropyl)acet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. British Journal of Cancer 72: 869–874.
[27]
Evans SM, Schrlau AE, Chalian AA, Zhang P, Koch CJ (2006) Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Dermatol 126: 2596–2606.
[28]
Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, et al. (2000) Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60: 2018–2024.
[29]
Busch TM, Wileyto EP, Evans SM, Koch CJ (2003) Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections. Adv Exp Med Biol 510: 37–43.
[30]
Douple EB, Totten MD, Spencer F (1988) Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin. NCI Monogr 129–132.
[31]
Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, et al. (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67: 4467–4473.
[32]
Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, et al. (2005) Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 4: 1417–1422.
[33]
Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, et al. (2004) Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10: 2512–2524.
[34]
Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, et al. (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76: 162–167.
[35]
Huang S-M, Bock JM, Harari PM (1999) Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck. Cancer Res 59: 1935–1940.
[36]
Chen DJ, Nirodi CS (2007) The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 13: 6555–6560.
[37]
Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, et al. (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182–31189.
[38]
Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, et al. (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65: 3328–3335.
[39]
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
[40]
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
[41]
Baselga J, Norton L, Masui H, Pandiella A, Coplan K, et al. (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327–1333.
[42]
Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, et al. (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909–916.
[43]
Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637–4642.
[44]
Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994–1003.
[45]
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885–4892.
[46]
Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166–2174.
[47]
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701–708.
[48]
Krause M, Baumann M (2008) Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev 27: 387–402.
[49]
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966.
[50]
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646–8654.
[51]
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–1127.
[52]
Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, et al. (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99: 1589–1594.
[53]
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.
[54]
Cai W, Chen X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49: Suppl 2113S–128S.
[55]
Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49: Suppl 2129S–148S.
[56]
Penet MF, Glunde K, Jacobs MA, Pathak AP, Bhujwalla ZM (2008) Molecular and functional MRI of the tumor microenvironment. J Nucl Med 49: 687–690.
[57]
Rajendran JG, Krohn KA (2005) Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43: 169–187.
